Literature DB >> 22985521

Genetics and pharmacogenomics of diffuse gliomas.

H F van Thuijl1, B Ylstra, T Würdinger, D van Nieuwenhuizen, J J Heimans, P Wesseling, J C Reijneveld.   

Abstract

Rapidly evolving techniques for analysis of the genome provide new opportunities for cancer therapy. For diffuse gliomas this has resulted in molecular markers with potential for personalized therapy. Some drugs that utilize pharmacogenomics are currently being tested in clinical trials. In melanoma, lung-, breast-, gastric- and colorectal carcinoma several molecular markers are already being clinically implemented for diagnosis and treatment. These insights can serve as a background for the promise and limitations that pharmacogenomics has for diffuse gliomas. Better molecular characterization of diffuse gliomas, including analysis of the molecular underpinnings of drug efficacy in clinical trials, is urgently needed. We foresee exciting developments in the upcoming years with clinical benefit for the patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22985521     DOI： 10.1016/j.pharmthera.2012.09.002

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  6 in total

1.  Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.

Authors:  Agustí Alentorn; Hinke F van Thuijl; Yannick Marie; Hussa Alshehhi; Catherine Carpentier; Blandine Boisselier; Florence Laigle-Donadey; Karima Mokhtari; Ilari Scheinin; Pieter Wesseling; Bauke Ylstra; Laurent Capelle; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Jaap C Reijneveld; Ahmed Idbaih
Journal:  Neuro Oncol       Date:  2013-12-12       Impact factor: 12.300

2.  Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.

Authors:  Maarten P G Massink; Irsan E Kooi; Saskia E van Mil; Ekaterina S Jordanova; Najim Ameziane; Josephine C Dorsman; Daphne M van Beek; J Patrick van der Voorn; Daoud Sie; Bauke Ylstra; Carolien H M van Deurzen; John W Martens; Marcel Smid; Anieta M Sieuwerts; Vanja de Weerd; John A Foekens; Ans M W van den Ouweland; Ewald van Dyk; Petra M Nederlof; Quinten Waisfisz; Hanne Meijers-Heijboer
Journal:  Mol Oncol       Date:  2015-01-13       Impact factor: 6.603

3.  Liquid biopsies in patients with diffuse glioma.

Authors:  Myron G Best; Nik Sol; Sebastiaan Zijl; Jaap C Reijneveld; Pieter Wesseling; Thomas Wurdinger
Journal:  Acta Neuropathol       Date:  2015-02-27       Impact factor: 17.088

4.  DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly.

Authors:  Ilari Scheinin; Daoud Sie; Henrik Bengtsson; Mark A van de Wiel; Adam B Olshen; Hinke F van Thuijl; Hendrik F van Essen; Paul P Eijk; François Rustenburg; Gerrit A Meijer; Jaap C Reijneveld; Pieter Wesseling; Daniel Pinkel; Donna G Albertson; Bauke Ylstra
Journal:  Genome Res       Date:  2014-09-18       Impact factor: 9.043

Review 5.  Personalized medicine in oncology. New perspectives in management of gliomas.

Authors:  Justyna Gil; Izabela Laczmanska; Karolina A Pesz; Maria M Sasiadek
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

6.  Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas.

Authors:  Hinke F van Thuijl; Ilari Scheinin; Daoud Sie; Agusti Alentorn; Hendrik F van Essen; Martijn Cordes; Ruth Fleischeuer; Anja M Gijtenbeek; Guus Beute; Wimar A van den Brink; Gerrit A Meijer; Miek Havenith; Ahmed Idbaih; Khê Hoang-Xuan; Karima Mokhtari; Roel Gw Verhaak; Paul van der Valk; Mark A van de Wiel; Jan J Heimans; Eleonora Aronica; Jaap C Reijneveld; Pieter Wesseling; Bauke Ylstra
Journal:  Genome Biol       Date:  2014-09-23       Impact factor: 13.583
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.